Interview with Martin Nelzow, CEO, Boehringer Ingelheim Brazil
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Address: Rochaverá Corporate Towers. Av. Nações Unidas, 14.171 – Torre Marble – 18º andar – São Paulo – SP. CEP: 04794-000
Tel: (11) 4949-4700
Web: http://www.boehringer-ingelheim.com.br/principal.asp
The Boehringer Ingelheim group is one of the top 20 pharmaceutical companies in the world. Headquartered in Ingelheim, Germany, operates globally with 138 affiliates in 47 countries and 41,300 employees. Since its founding in 1885, this family business is committed to researching, developing and marketing novel products of high therapeutic value for human and veterinary medicine.
Present in Brazil since 1956, headquartered in Sao Paulo and factory in Itapecerica da Serra (SP), the company employs approximately 1,000 employees and sells products with brands like Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton , and several prescription products, with an outstanding performance in the areas respiratory, cardiovascular, Parkinson’s and others.
Located in Itapecerica da Serra, São Paulo, the Brazilian plant has excellence in the manufacture of medicines and is one of the largest and most modern of the group in the world, accounting for the 3rd largest production volume, representing 10% of the company’s global . Through its Industrial Business Area, the plant of Boehringer Ingelheim in Brazil also produces products for other laboratories.
Since 1998, Boehringer Ingelheim has been designated by the Great Place to Work Institute as one of the 100 best companies to work in Brazil. In total, there have been nine nominations, eight of them consecutive. Since 2004 the company has also been designated by the Great Place to Work as one of the best companies to work in Latin America.
Anador ®, Bisolvon ®, Buscopan ®, Dulcolax ®, and Mucosolvan ® ® Pharmaton
You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three…
Dr. Ogari Pacheco, president of the Board of Directors for Cristália, highlights the unique journey for Cristália over the past 45 years, as one of the most innovative local pharma…
Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for…
Jaime Rabi, director of Microbiológica, documents the unique development path of the company and its pioneering contribution to the production of antiretroviral medicines in Brazil, as well as its international…
Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by…
Marco Fireman, vice-minister and chairman of the National Commission for the Incorporation of Technologies (CONITEC); a board that advises the Brazilian Ministry of Health on the inclusion of new health…
Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness…
Nelson Mussolini, executive president of the syndicate of the pharmaceutical industry in the State of Sao Paulo (Sindusfarma), which represents around 95 percent of all pharmaceutical marketing in the country…
Antonio Britto, the executive president of Interfarma, the main association gathering together local and international innovators in Brazil, provides insights into some of the hottest topics in Brazil’s pharmaceutical sector,…
Eduardo Martins, president director of Pharlab, provides insights into the “2020 vision” that has been driving the eye-catching development of this ambitious domestic company and documents how Pharlab is leveraging…
Nilton Paletta, President Latin America at IQVIA™ and responsible for the company’s operations in 18 countries in the region, provides insights into the most impactful dynamics shaping the Brazilian pharmaceutical…
Guilherme Maradei, managing director of Merck Brazil and general manager Biopharma, documents the eye-catching growth that the Brazilian affiliate has been experiencing over the past two years and provides insights…
Alexandre França, CEO of Aspen Pharma Brazil, describes the transformation of the Brazilian organization over the past year, which allowed Aspen Brazil to establish itself as the best performing affiliate…
See our Cookie Privacy Policy Here
